Ferid Murad, M.D., Ph.D.
Professor and Director Emeritus
The Brown Foundation
Institute
of Molecular Medicine
Director, IMM Center for Cell Signaling
Texas Nobel Scholar, The University of Texas at Houston
Director, UT Health Science Center at Houston Program in Intracellular Signaling
1998 Nobel Laureate in Physiology or Medicine
phone 713.500.2433;
fax 713.500.2498
Ferid.Murad@uth.tmc.edu
Nobel Laureate Ferid Murad, M.D. is Director Emeritus of the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, Director of the IMM Center for Cell Signaling, Regental Professor and John S. Dunn Sr. Distinguished Chair in Physiology and Medicine, Texas Nobel Scholar at the University of Texas at Houston, and Director of the UT Health Science Center at Houston Program in Intracellular Signaling.
Dr. Murad completed his undergraduate work at DePauw University and received his M.D. and Ph.D. from Case Western Reserve University. He had a medical residency at Massachusetts General Hospital and a fellowship at NIH in the Heart Institute. He was on the faculty at the University of Virginia 1970-81 as Director of the Clinical Research Center and Director of the Division of Clinical Pharmacology with appointments in Medicine and Pharmacology. He was Chief of Medicine at Palo Alto Veterans Hospital 1981-88, Associate Chairman of Medicine 1982-86 and Chairman of Medicine 1986-88 at Stanford University. He was Vice President of Research and Development at Abbott Laboratories 1988-93 and Professor at Northwestern University.
Dr. Murad has been active in both academic medicine and industry throughout his distinguished career. He has founded or co-founded five biotechnology companies and has advised many cities and government leaders about technology development. His work has concentrated on the field of cell signaling and signal transduction systems.
In 1998, Dr. Murad received the Nobel Prize in Medicine for his work with nitric oxide – a colorless, odorless gas that signals blood vessels to relax and widen, which in turns lowers blood pressure. He continues research which leads to a better understanding of how information is transmitted between cells.
Among his many other awards and honors, Dr. Murad received the prestigious Albert and Mary Lasker Basic Medical Research Award in 1996, the American Heart Association Ciba Award in 1988, and the Baxter Award for Distinguished Research in the Biomedical Sciences from the Association of American Medical Colleges in 2000. He also received the American Society of Clinical Pharmacology Distinguished Research Prize in 2005 and the President’s Scholar Award from the University of Texas-Houston Health Science Center in 2006.
He is a member of the National Academy of Sciences, a member of the Institute of Medicine of the National Academy of Sciences, Fellow of the American Academy of Arts and Sciences, member of Texas Academy of Medicine, Engineering and Science Technology. He is also a member of several foreign academies and is an Honorary or Adjunct Professor at a number of universities. Dr. Murad also serves on the Board of Directors or Scientific Advisory Boards of a number of public and private companies and various foundations and universities. About 140 trainees have worked with him in his laboratories who are currently academic or pharmaceutical industry leaders around the world.
Research Projects:
Dr. Murad’s research with cell signaling focuses on the nitric oxide/cyclic GMP pathways to identify novel molecular pathways and targets that can lead to the discovery and development of novel therapeutic agents. His laboratory in the IMM is typically 18 to 20 scientists. He also has a similar sized laboratory at the Shanghai University examining the effects of Traditional Chinese medicines on the NO/cGMP pathways.
For more information see the Nobel Foundation website at <www.nobel.se>
Recent Publications (24 of 407):
Turko I, Murad F. Protein nitration in cardiovascular diseases. Pharmacological Reviews 54, 619-634, 2002.
Bian K, Murad F. Nitric oxide (NO) – Biogeneration, regulation, and relevance to human diseases. Frontiers in Bioscience 8, 264-278, 2003.
Bian K, Gao Z, Weisbrodt N, Murad F. The nature of heme/iron-induced protein tyrosine nitration. Proc. Nat. Acad. Sci. 100, 5712-5717, 2003.
Turko I, Li L, Aulak K, Stuehr D, Chang R, Murad F. Protein tyrosine nitration in the mitochondria from diabetic mouse heart. J. Biol. Chem. 278, 33972-33977, 2003.
Martin E, Sharina I, Kots A, Murad F. A constitutively activated mutant of human soluble guanylyl cyclase. Implication for the mechanism of soluble guanylyl cyclase activation. Proc. Nat. Acad. Sci. 100, 9208-9213, 2003.
Sharina I, Martin E, Thomas A, Davis K, Murad F. CCAAT binding factor regulates expression of the β1 subunit of soluble guanylyl cyclase gene in the BE2 human neuroblastoma cell line. Proc. Nat. Acad. Sci. 100 (20), 11523-8, 2003.
Hanafy KA, Martin, E, Murad F. CCTη: A novel soluble guanylyl cyclase interacting protein. J. Biol. Chem. 279, 46946-46953, 2004.
Murad F. Discovery of some of the biological effects of nitric oxide and its role in cell signaling. Bioscience Report 24, 452-474, 2004.
Murad F. Some highlights of a 47 year career in research. Cellular and Molecular Life Sciences 62, 1-3, 2005.
Martin E., Czamecki K, Jayaraman V, Murad F, Kincaid JR. Resonance Raman and infrared spectroscopic studies of high-output forms of human soluble guanylyl cyclase. J. Amer. Chem. Soc. 127, 4625-4631, 2005.
Bian K, Zhang M, Harari Y, Lai M, Weisbrodt N, Murad F. Helminth regulation of host IL-4Rd/Stat 6 signaling: Mechanism underlying NOS-2 inhibition by Tripinella spiralis. Proc. Nat. Acad. Sci. 102, 3936-3941, 2005.
Martin E, Berka V, Tsai AL, Murad F. Soluble guanylyl cyclase: The nitric oxide receptor. Methods in Enzymology. 396, 478-492, 2005.
Bian K, Murad F. Nitric oxide biology and atherosclerosis. Chapter in Current Topics in Atherosclerosis Research, Nova Publishers, 2005.
Krumenacker J, Kots A, Murad F. Effects of the c-Jun kinase inhibitor anthral [1,9-cd] pryazole-6(2H)-one (SP600125) on soluble guanylyl cyclase α1 gene regulation and cGMP synthesis. Amer. J. Physiol. Cell Physiol. 289:C778-C784, 2005.
Martin E, Sharina I, Seminara AR, Krumenacker J, Murad F. Nitric oxide cell signaling mediated by cGMP. Nitric Oxide Cell signaling and Gene Expression.Chapter 7: 166-212, 2005.
Krumenacker J, Katsuki S, Kots A, Murad F. Differential expression of genes involved in cGMP-dependent nitric oxide signaling in murine embryonic stem (ES) cells and ES cell-derived cardiomyocyte precursors. Nitric Oxide 14, 1-11, 2006.
Zhang Q, Madonna R, Shen W, Perin E, Murad F, Yeh E, Buja LM, DeCaterina R, Willerson JT, Geng YJ. Stem cells and cardiovascular tissue repair: Mechanism, Methods and Clinical applications. J. Cardiothoracic-Renal Research 1, 3-14, 2006.
Krumenacker J, Murad F. NO cGMP signaling in development and stem cells. Molecular Genetics and Metabol. 87, 311-314, 2006.
Bian K, Ke Y, Kamisaki Y, Murad F. Proteonomic modification by nitric oxide. J. Pharmacol. Sci. 101, 271-279, 2006.
Murad F. Shattuck Lecture: Discovery of nitric oxide and cyclic GMP in cell signaling and their role in drug development. New England J. Med. 355, 2003-2011, 2006.
Zhu H, Bian K, Murad F. Nitric oxide accelerates the recovery from burn wounds. World J. of Surgery. 30, 1-9, 2007.
Mujoo K, Krumenacker J, Wada Y, Murad F. Differential expression of nitric oxide signaling components in undifferentiated and differentiated human embryonic stem cells. Stem Cells and Development (In press).
Bian K, Murad F. Nitric oxide signaling in vascular biology. J. Amer. Soc. Hypertension (In press).
Taub E, Murad F, Oliphant D. The Wellness Solution. World Almanac Library, 282 pgs, 2007.